Skip to main content
Clinical Trials/NCT03996954
NCT03996954
Unknown
Not Applicable

Validation of a Smartphone-based Recorder for Detection of Cardiac Arrhythmias

Blackpool Teaching Hospitals NHS Foundation Trust1 site in 1 country400 target enrollmentOctober 8, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiac Arrhythmia
Sponsor
Blackpool Teaching Hospitals NHS Foundation Trust
Enrollment
400
Locations
1
Primary Endpoint
Diagnostic accuracy of alivecor recording
Last Updated
5 years ago

Overview

Brief Summary

The investigators will evaluate the diagnostic yield of the new AliveCor device versus a 12 lead ECG when used simultaneously to detect cardiac arrhythmia

Detailed Description

The investigators are planning to record 250 pre-defined abnormal ECGs (50 each of atrial fibrillation, atrial flutter, pre-excitation, ventricular tachycardia, , supraventricular tachycardia) and 150 control ECGs (100 sinus rhythm, 50 sinus tachycardia) using both the AliveCor Smartphone device and a 12-lead ECG. All 400 ECGs will then be read by 3 blinded reporters - a Consultant Electrophysiologist, a Consultant General Cardiologist and a General Practitioner. The output of the AliveCor automatic detection algorithm will also be recorded as a fourth reporter. The screening characteristics of all 4 reporters using the AliveCor device vs the definitive 12 lead ECG will be analysed and compared.

Registry
clinicaltrials.gov
Start Date
October 8, 2018
End Date
October 7, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Khalid Abozguia

Consultant Cardiologist and Electrophysiologist

Blackpool Teaching Hospitals NHS Foundation Trust

Eligibility Criteria

Inclusion Criteria

  • Male or female patients \>18 years
  • 12 lead ECG finding of arrhythmia, manifest pre-excitation, pacing rhythm (in the EP lab), sinus rhythm or sinus tachycardia

Exclusion Criteria

  • Age \<18 years
  • Patients unable to or unwilling to use the device
  • Patients with cardiac pacemaker, ICDs, or other implanted electronic devices

Outcomes

Primary Outcomes

Diagnostic accuracy of alivecor recording

Time Frame: Diagnostic accuracy of Alivecor recording at the end of the study which will be 2 years after study start date.

For each patient two diagnoses of their underlying heart rhythm will be provided by blinded reporters. The percentage match of these diagnoses (the ratio of identical diagnoses to mismatch in diagnoses between ECG report and Alivecor report will be used as a measure of accuracy of the Alivecor to differentiate between different heart rhythms, using the 12 lead ECG as the gold standard for cardiac rhythm diagnosis.

Study Sites (1)

Loading locations...

Similar Trials